Mechanical Circulatory Support by O\u27Neill, Brian P
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Cardiology Articles Cardiology/Cardiovascular Research 
4-1-2021 
Mechanical Circulatory Support in Acute Myocardial Infarction 
and Cardiogenic Shock 
Alejandro Lemor 
Lina Ya'qoub 
Mir B. Basir 





Alejandro Lemor, MD, MSca, Lina Ya’qoub, MDb,
Mir B. Basir, DO, FSCAIa,c,*
KEYWORDS
 Acute myocardial infarction  Cardiogenic shock  Mechanical circulatory support
 Intra-aortic balloon pump  Extracorporeal membrane oxygenation  TandemHeart  Impella
KEY POINTS
 Acute myocardial infarction complicated by cardiogenic shock is a deadly condition associated
with significant morbidity and mortality.
 Despite 20 years of medical advancements, early revascularization remains the sole therapy
proven to improve outcomes.
 Mechanical circulatory support devices provide a physiologically plausible mechanism of
improving outcomes by offering hemodynamic stability for revascularization and improving
end-organ perfusion. Results from well-powered randomized controlled trials, however, are
not yet available.
 Randomized controlled trials have been difficult to conduct in this patient population; until such
trials are performed, implementing shock teams and protocols has been associated with
improved outcomes in observational studies and may be considered.
 Technological advancements will lead to continued development of more mobile, smaller-
caliber, and more powerful mechanical circulatory support devices. Understanding the
mechanisms of action and physiologic effects of these devices, therefore, is critically important.
INTRODUCTION
Acute myocardial infarction (AMI) can result in
diastolic dysfunction and an increase in left ven-
tricular end-diastolic pressure. If not treated
promptly, AMI can progress to systolic dysfunc-
tion and decreasing stroke volume, which can
lead to cardiogenic shock (CS). CS is a low-
output state resulting in decreased systemic
and coronary perfusion. Decreased systemic
perfusion results in end-organ injury, whereas
decreased coronary perfusion results in further
ischemia, leading to a vicious cascade that ulti-
mately can lead to death. The cascade of events
results in a complex neurohumoral cascade
referred to as the systemic inflammatory
response syndrome. The goals for treating AMI
and CS (AMICS), therefore, are to relieve
ischemia and improve perfusion to end organs.1
AMICS is a deadly condition associated with
significant morbidity and mortality. Patients pre-
senting with AMICS who do not receive invasive
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therapies have less than 20% survival.2 The
Should We Emergently Revascularize Occluded
Coronaries for Cardiogenic Shock (SHOCK) trial
demonstrated improved survival in patients pre-
senting with AMICS treated with early mechani-
cal revascularization.3 Unfortunately, further
revascularization does not lead to further im-
provements in short-term survival, as was
demonstrated in the CULPRIT-SHOCK trial.4 In
the past 2 decades, there has been little
advancement made to improving outcomes
further. This is of great concern because the
prevalence of AMICS is growing in the aging
population.5 Patients frequently present with
more comorbidities and are more likely to expe-
rience cardiac arrest and CS.5
Given the high mortality associated with
AMICS despite revascularization, clinicians have
looked to other forms of therapies in the hope
of improving outcomes. Technological advance-
ments have resulted in an increased availability
of temporary mechanical circulatory support
(MCS) devices, which can improve systemic and
coronary perfusion. These devices are reviewed
herein.
INTRA-AORTIC BALLOON PUMP
Intra-aortic balloon pump (IABP) counterpulsa-
tion is the oldest and most common form of
MCS.6–8 Since its inception in 1967, several
observational studies have suggested improved
survival with the use of IABP in patients with
AMICS9–21 (Table 1). IABPs have been demon-
strated to improve systemic hemodynamics
and improve coronary perfusion, are easy to
use, and are inexpensive. Until recently, there
was 1 alternative device, venoarterial (VA)–extra-
corporeal membrane oxygenation (ECMO),
which was more invasive, associated with more
complications, and utilized primarily in select ter-
tiary care centers. Therefore, the use of IABPs
was questioned infrequently for decades.
Randomized controlled trials (RCTs), howev-
er, failed to show survival benefit22–26 (Table 2).
In the Thrombolysis and Counterpulsation to
Improve Cardiogenic Shock (TACTICS) trial, 57
patients with AMICS were randomized after
thrombolytic therapy to 48 hours of IABP ther-
apy or optimal medical therapy. The investiga-
tors found no significant difference in 6-month
mortality between the 2 groups.22 Prondzinsky
and colleagues24 randomized 45 patients with
AMICS after percutaneous coronary intervention
(PCI) to IABP therapy or optimal medical ther-
apy. They found no difference in Acute Physi-
ology and Chronic Health Evaluation II scores,
interleukin-6 levels, and cardiac index (CI) be-
tween the groups. In-hospital mortality also
was similar between the groups (38.6% vs
28.6%, respectively).24 The largest trial conduct-
ed evaluating the efficacy of IABP in AMICS was
the IABP-SHOCK II trial; 300 patients were ran-
domized to IABP and 298 patients to the control
group. There was no difference in outcomes,
including secondary endpoints, such as time to
hemodynamic stabilization, length of stay in
the intensive care unit, serum lactate levels,
dose and duration of catecholamine therapy,
renal function, major bleeding, peripheral
ischemic complications, and stroke.25,26
Furthermore, numerous meta-analyses have
investigated the role of routine IABP in
AMICS.27–29 The largest analysis was performed
by Ahmad and colleagues,27 who analyzed pa-
tients presenting with AMI from 12 RCTs,
including 2123 patients, and 15 observational
studies, including 15,530 patients. They found
no difference in 30-day mortality in patients
with AMI who received IABP, regardless of the
presence (odds ratio [OR] 0.94; 95% CI, 0.69–
1.28) or absence (OR 0.98; 95% CI, 0.57–1.69)
of CS.28 As a result of these randomized trials
and meta-analyses, the European guidelines
downgraded IABP use in AMICS from a previous
class I to a class III recommendation,30 whereas
the US guidelines downgraded IABP use to a
class II recommendation.31
This review focuses on patients with AMICS.
Patients who present with CS from decompen-
sated heart failure CS, however, differ in their
response to IABPs. Malick and colleagues32
have demonstrated that patients with decom-
pensated heart failure CS had a 5-fold greater
cardiac output augmentation with IABP
compared with patients with AMICS.
VENOARTERIAL–EXTRACORPOREAL
MEMBRANE OXYGENATION
VA-ECMO uses a centrifugal pump and a mem-
brane oxygenator, to provide flows of up to 3 L/
min to 7 L/min. There are few retrospective
observational studies evaluating the use of
ECMO in AMICS (Table 3). These studies
demonstrate a survival rate ranging from 47%
to 60.9% in patients who have a mean age of
54 years to 60 years.33,34 In 2010, Sheu and col-
leagues35 studied 115 patients with AMICS from
1993 to 2002 without ECMO support and
compared them with 219 patients with AMICS
from 2002 to 2009 with ECMO support. The
30-day mortality for patients with ECMO was
lower than the non-ECMO cohort (30.1% vs
Lemor et al170
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41.7%, respectively; P 5 .034). A subgroup anal-
ysis of patients in profound CS found a signifi-
cant difference in mortality between groups
(39.1% in ECMO vs 72% in non-ECMO;
P5 .008); however, in patients without profound
shock, there was no significant difference in 30-
day mortality between the groups (26.1% vs
21.9%, respectively; P 5 .39). Esper and col-
leagues36 studied 18 patients who underwent
VA-ECMO in the catheterization laboratory for
AMICS and found an in-hospital survival rate of
67% and 6-month survival of 55%. More than
one-third of patients had an IABP placed and
were on vasopressors or inotropes. Similarly,
Negi and colleagues37 studied 15 patients with
AMICS (one-third presenting with cardiac arrest)
and showed a 47% survival rate. More than 90%
of patients were on 1 to 2 inotropes at the time
of ECMO, 60% had an IABP, and the vascular
complication rate was greater than 50%. Lastly,
a recent observational study by Vallabhajosyula
and colleagues38 using the National Inpatient
Sample database evaluated 2962 patients in a
period of 14 years and demonstrated a survival
rate of 40.8%. There was a significant trend to
improved survival over time and 12% of patients
were bridged to LV assist device (LVAD) or heart
transplantation.38
There are no RCTs to date evaluating the use
of ECMO in AMICS. Two European studies,
EURO SHOCK and ECLS-SHOCK, currently are
enrolling patients. EURO-SHOCK will randomize
428 patients to ECMO or standard therapy and
will evaluate 30-day mortality as the primary
outcome; their expected study completion
date is February 2024.39 Similarly, ECLS-
SHOCK will enroll 420 patients with AMICS un-
dergoing revascularization and randomize to
ECMO or medical therapy alone. The primary
outcome is 30-day mortality and the estimated
study completion date is August 2023.40
TandemHeart
TandemHeart (LivaNova, London, UK) used a
percutaneous centrifugal pump to provide flows
up to 3 L/min to 5 L/min using cannulas similar to
VA-ECMO. There are few studies assessing the
Table 2
Summary of randomized clinical trials of intra-aortic balloon pump in acute myocardial infarction and
cardiogenic shock
Author, Year Published Number of Patients Population Outcomes
Ohman
et al,22 2005
57 patients AMICS who
received
thrombolytics
No difference in 6-mo mortality
(34% for
IABP 1 thrombolytics vs 43%
for thrombolytics alone
[n 5 27]; adjusted P 5 .23)
Prondzinsky
et al,24 2010
45 patients AMICS status
post-PCI








598 patients AMICS No difference in 30-d mortality,
the time to hemodynamic
stabilization, the length of
stay in the intensive care unit,
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hemodynamic and clinical outcomes of Tandem-
Heart in patients with AMICS (Table 4). Kar and
colleagues41 studied 80 patients with AMICS
and found that TandemHeart led to a rapid
improvement several hemodynamic measures,
including CI, systolic blood pressure, urine
output, and lactic acid levels. The mortality rates
were 40.2% and 45.3% at 30 days and 6 months,
respectively, for AMICS patients. Smith and col-
leagues42 analyzed 56 patients, 16 (29%) of
whom had AMICS, and found improved hemo-
dynamics with the use of TandemHeart. They
also found that survival was significantly influ-
enced by the indication of the TandemHeart
(23.8% in bridge to recovery vs 51% in bridge
to LVAD or surgery [P 5 .04]), and patients
who did not receive definitive therapy had
poor outcomes (13.8% survived to hospital
discharge). Further observational data are being
collected in the TandemHeart Experiences and
MEthods (THEME Registry); an ongoing
multicenter study (ClinicalTrials.gov Identifier:
NCT02326402).
Two underpowered RCTs have been conduct-
ed with the use of TandemHeart. Thiele and col-
leagues43 randomized 20 patients to IABP and
21 patients to TandemHeart. They found cardiac
power index and other hemodynamics measures
improved more effectively with TandemHeart;
however, complications, including severe
bleeding and limb ischemia, were more
frequent. The investigators also found no differ-
ence in 30-day mortality between groups; how-
ever, the study was underpowered to detect
these differences.43 Burkhoff and colleagues44
randomized 33 patients with AMICS to treat-
ment with IABP or TandemHeart. They similarly
found improved hemodynamics with higher CI
and lower pulmonary capillary wedge pressure
with the use of TandemHeart; however, there
was no difference in 30-day mortality between
the groups.44
Table 3
Major observational studies of venoarterial–extracorporeal membrane oxygenation in acute
myocardial infarction and cardiogenic shock
Observational Studies
Author/Trial (Year) Sample Size Device (s) Results Notes
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IMPELLA
Impella (Abiomed, Danvers, Massachusetts) is
continuous nonpulsatile micro-axial pump that
has an inlet area that aspirates blood from the
left ventricle and ejects it through the outlet
into the ascending aorta, at a rate up to 5.5 L/
min. Observational studies assessing the use of
Impella in CS have compared it with either med-
ical therapy, IABP, or ECMO (Table 5). The
Impella-EUROSHOCK registry was an
observational-single arm study that evaluated
120 patients with AMICS supported with an
Impella 2.5. The feasibility study demonstrated
a 64% 30-day mortality; however, it showed
feasibility of device placement and improvement
in lactate levels.45 Karatolios and colleagues46
compared Impella to medical therapy in 90 pa-
tients with cardiac arrest (27 patients were
treated with Impella) and demonstrated 65%
survival in the Impella cohort compared with
20% in the medical therapy cohort. Schrage
and colleagues47 matched patients from the
IABP-SHOCK II trial to patients supported with
an Impella device in Europe. They demonstrated
no significant difference in 30-day all-cause mor-
tality (48.5% vs 46.4%, respectively; P 5 .64) but
did show higher rates of severe bleeding and
vascular complications in the Impella group.
The main limitation of this study was that the de-
gree of CS was not taken into account when
matching patients. Lemor and colleagues48
analyzed AMICS patients from the National
Inpatient Sample from 2015 to 2017 who under-
went PCI and had either Impella or ECMO sup-
port. Propensity-matched analysis showed
significantly lower mortality in the Impella cohort
(26.7% vs 43.3%, respectively; P 5 .02) as well as
lower ischemic stroke and vascular complication
rates. This study, however, also was limited by
the inability to match patients according to the
degree of shock. Loehn and colleagues49
showed improved survival with the use of
Impella before PCI (50% pre-PCI Impella vs
23.1% post-PCI Impella). Helgestad and col-
leagues50 demonstrated lower 30-day mortality
in patients receiving Impella compared with a
matched control group that underwent IABP
placement (40% vs 77.5%, respectively; P log
rank <0.001).
Table 4





Patients Study Type Outcomes
Thiele
et al, 2005
41 RCT: IABP vs
TandemHeart
No difference in 30-d mortality.
TandemHeart led to improvement






33 RCT: IABP vs
TandemHeart
No difference in 30-d mortality.










30-d and 6-mo mortality rates were
40.2% and 45.3%, respectively, in
AMI, vs 32% and 35%, respectively,
in NICM.










Survival was significantly influenced
by indication (23.8% in bridge to
recovery vs 51% in bridge to LVAD
or surgery; P 5 .04). TandemHeart







Observational 30-d mortality 63%
Abbreviations: NICM, nonischemic cardiomyopathy; PCWP, pulmonary capillary wedge pressure.
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Table 5
Summary of randomized controlled trials and observational studies for Impella
Randomized Controlled Trials
Author/
Trial (Year) Sample Size Comparison Results Notes
ISAR-SHOCK51
(2008)















P 5 .92) and
6 mo mortality
(50% for both; P 5 .9)
>90% of patients with cardiac
arrest prior device placement
Observational studies
Author/Trial (Year) Sample Size Device (s) Results Notes
INOVA60 (2019) 82 IABP, Impella,
ECMO
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Lactate <4 and cardiac power
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Two underpowered RCTs have been conduct-
ed evaluating Impella in AMICS. Both compared
Impella versus IABP in a small sample of pa-
tients. The ISAR-SHOCK trial randomized 25 pa-
tients to either Impella 2.5 or IABP and
demonstrated safety and feasibility to use
Impella 2.5 in AMICS. Patients treated with
Impella had similar 30-day mortality when
compared with IABP (46%); however, Impella
did provide better hemodynamic support.51
The IMPella versus IABP Reduces mortality in
STEMI patients treated with primary PCI in Se-
vere cardiogenic SHOCK (IMPRESS) trial was a
randomized, prospective, open-label, multi-
center trial that enrolled 48 patients with AMICS
and randomized patients to an Impella CP or
IABP.52 The investigators aimed to enroll more
than 100 patients but the trial was prematurely
stopped due to poor enrollment. Overall, the re-
sults showed similar mortality rates for both co-
horts (46% for Impella and 50% for IABP; P 5 .9).
RIGHT VENTRICULAR FAILURE
Acute right coronary artery occlusion proximal
to the right ventricular (RV) branches, or less
commonly left circumflex artery occlusion, often
results in RV ischemia. RV ischemia can lead to
depressed RV systolic function decreasing trans-
pulmonary flow and left ventricular filling. This
can result in diminished preload and cardiac
output. The severity of the hemodynamic
compromise in patients with RV failure is related
to the extent of RV ischemia, left ventricular
function, and ventricular interdependence.53 Pa-
tients with RV dysfunction are prone to bradyar-
rhythmias, which can further decrease cardiac
output. Hemodynamic compromise from RV fail-
ure, therefore, should be treated first with vol-
ume resuscitation, restoration of physiologic
rhythm or pacing, and inotropic agents. Patients
with persistent RV failure can be considered for
RV MCS devices.
In patients with left ventricular dysfunction,
increased left ventricular pressures and pulmo-
nary venous pressures lead to increased RV
afterload, which further decreases RV output.
Lala and colleagues54 analyzed patients from
the SHOCK trial, which recruited primarily pa-
tients with left ventricular failure and found
that the prevalence of RV failure (ie, biventricular
failure) was 38%. They defined RV failure using
hemodynamic parameters: central venous pres-
sure greater than 10 mm Hg, central venous
pressure/pulmonary capillary wedge pressure
greater than 0.63, pulmonary artery pulsatility in-
dex less than 2, and RV stroke work index less
than 450 g*m/m2. Using similar definitions, Basir
and colleagues demonstrated similar findings in
the National Cardiogenic Shock Initiative (NCSI)
and identified these patients as having increased
mortality compared with those with isolated left
ventricular failure.
VA-ECMO is a powerful RV assist device
(RVAD), and, in the setting of concomitant left
sided failure, may be the preferred modality of
MCS, because it provides biventricular support.
Unfortunately, data on its use specifically for
RV failure in the setting of AMICS are limited.
The Impella RP is a percutaneous microaxial
pump designed to support the RV. There are
few data demonstrating the impact of Impella
RP on outcomes in patients with RV dysfunction
(Table 6). Cheung and colleagues55 studied 18
patients, 39% of whom had AMI and found
that Impella RP led to improvements in hemody-
namic measures and reported a 30-day survival
rate of 72% and a 1-year survival rate of 50%.
The RECOVER RIGHT study included 30 patients
with RV failure refractory to medical therapy.
The investigators found that patients had
improvement in hemodynamics with the use of
an Impella RP. Overall, 73.3% of patients sur-
vived to 30 days.56
TandemHeart–RVADs (TH-RVADs) use an
extracorporeal centrifugal flow pump and 2
venous cannulas to deliver blood from the right
atrium (RA) to the main PA via bilateral femoral
venous cannulation. A 21F inflow cannula is
placed in the RA and a second 21F outflow can-
nula is inserted into the main PA. Usually, the
outflow cannula is placed in the main PA via
the right femoral vein, and the inflow cannula is
placed in the RA via the left femoral vein. If the
distance from femoral vein to fifth intercostal
space exceeds 58 cm or femoral access cannot
be used, the internal jugular venous access can
be utilized. There also is a ProtekDuo (LivaNova,
London, UK) dual-lumen cannula, which can be
placed in the right internal jugular vein. It con-
tains 2 lumens within one 29F or 31F cannula,
taking blood from RA to the extracorporeal
pump then delivering it to the PA. There are
few data on the use of TH-RVAD on outcomes
(see Table 5). Kapur and colleagues57 retrospec-
tively studied outcomes in 46 patients with RV
failure who received a TH-RVAD, of whom 21 pa-
tients were cannulated percutaneously. TH-
RVAD implantation was associated with a signif-
icant decrease in RA pressure and a significant
increase in CI. In-hospital mortality was 33% in
patients with AMI. In another study by Kapur
and colleagues,58 9 patients, 6 of whom had
AMI, had improved hemodynamics when
Lemor et al178
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treated with TH-RVAD, with an in-hospital mor-
tality rate of 44%.
SHOCK PROTOCOLS AND TEAMS
Shock protocols allow for a uniform treatment
strategy in an effort to provide patients, nurses,
and clinicians a systematic pathway of care,59
although shock teams provide a diverse set of
options that can be catered to the individual pa-
tient, taking into account operator and institu-
tional expertise.60 This concept is best
exemplified in the work of the NCSI. Investiga-
tors involved in the study began by reviewing
outcomes data in AMICS and forming best prac-
tices, which were put together into a shock pro-
tocol. The study was limited to evaluating
outcomes in patients with AMICS and not other
shock phenotypes. The study also used inclusion
and exclusion criteria similar to previous RCTs in
an effort to compare with prior work.
The shock protocol was piloted in metro
Detroit and named the Detroit Cardiogenic
Shock Initiative.61 A 41-patient pilot study found
Table 6


































































Abbreviations: MAP, mean arterial pressure; PA, pulmonary artery.
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the protocol could be used across selected cen-
ters and was associated with high survival
compared with historical studies and local out-
comes. The study then was expanded and
renamed the NCSI. The goal was to see if the
shock protocol could be reproduced in centers
across the United States. In total, greater than
60 sites were recruited with a goal of enrolling
400 patients. The NCSI is the first contemporary
study to evaluate outcomes of a shock protocol.
The best practices included in the protocol are1
to identify AMICS early and treat patients in the
catheterization laboratory (early is defined
as <90 minutes to 120 minutes of diagnosis
and prior to escalating use of inotropes)2; place-
ment of Impella prior to PCI, because PCI can
result in reperfusion injury, distal embolization,
and transient cessation of coronary perfusion
with balloon inflations and stents, which are bet-
ter tolerated with MCS; and3 use of pulmonary
artery catheters to assess patients underlying
hemodynamic state and to guide further ther-
apy, including escalation of MCS, identification
of RV failure, and weaning. The study has
Fig. 1. The 50-year mortality trend in AMI complicated by CS. Over 50 years, mortality in AMI with CS has
increased steadily from approximately 80% to close to 30%. (Adapted from Goldberg RJ, Spencer FA, Gore
JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital
death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based
perspective. Circulation. 2009;119(9):1211-1219; with permission.)
Fig. 2. Key components of a CS
team. Using a shock team and pro-
tocol has been associated with
improved outcomes in numerous
observational studies. Early triage,
prompt identification, and rapid de-
livery of MCS based on a patient’s
physiologic state are steps impor-
tant in CS management. A multidis-
ciplinary team–based approach,
which includes interventional cardi-
ology, advanced heart failure, car-
diac surgery, and critical care, has
proved efficient in improving out-
comes without delaying care and it
is highly recommended in clinical
practice. Early identification of shock starts in the emergency department and the decision to send a patient to
the catheterization laboratory should not be delayed, which highlights the importance of good communication be-
tween the emergency department and the cardiology team. Escalation for additional left ventricle or RV support as
well as transfer to a tertiary care center (if needed) should be discussed early by the multidisciplinary team.
Lemor et al180
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enrolled more than 300 patients with AMICS and
has demonstrated survival to hospital discharge
greater than 70%.62,63
SUMMARY
AMI complicated by CS is a deadly condition
associated with significant morbidity and mortal-
ity (Fig. 1). Despite 20 years of medical advance-
ments, early revascularization remains the sole
therapy proved to improve outcomes. MCS de-
vices provide a physiologically plausible mecha-
nism of improving outcomes by offering
hemodynamic stability for revascularization and
improving end-organ perfusion. Results from
well-powered RCTs, however, are not yet avail-
able. RCTs have been difficult to conduct in
this patient population; until such trials are per-
formed, implementing shock teams and proto-
cols has been associated with improved
outcomes in observational studies and may be
considered (Fig. 2). Technological advance-
ments will lead to continued development of
more mobile, smaller-caliber, and more power-
ful MCS devices. Understanding the mechanism
of action and physiologic effects of these de-
vices, therefore, is critically important.
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